Paratek Pharmaceuticals Current Valuation vs. Price To Sales

PRTKDelisted Stock  USD 2.18  0.00  0.00%   
Based on Paratek Pharmaceuticals' profitability indicators, Paratek Pharmaceuticals may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Paratek Pharmaceuticals' ability to earn profits and add value for shareholders.
For Paratek Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Paratek Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Paratek Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Paratek Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Paratek Pharmaceuticals over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
Please note, there is a significant difference between Paratek Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Paratek Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Paratek Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Paratek Pharmaceuticals Price To Sales vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Paratek Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Paratek Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Paratek Pharmaceuticals is regarded third in current valuation category among its peers. It is rated below average in price to sales category among its peers . The ratio of Current Valuation to Price To Sales for Paratek Pharmaceuticals is about  403,481,972 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Paratek Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

Paratek Current Valuation vs. Competition

Paratek Pharmaceuticals is regarded third in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 1.78 Billion. Paratek Pharmaceuticals retains roughly 345.3 Million in current valuation claiming about 19% of equities under Health Care industry.

Paratek Price To Sales vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Paratek Pharmaceuticals

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
345.3 M
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Paratek Pharmaceuticals

P/S

 = 

MV Per Share

Revenue Per Share

 = 
0.86 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.

Paratek Price To Sales Comparison

Paratek Pharmaceuticals is currently under evaluation in price to sales category among its peers.

Paratek Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Paratek Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Paratek Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Paratek Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Paratek Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts. Paratek Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 207 people.

Paratek Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Paratek Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Paratek Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Paratek Pharmaceuticals' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Paratek Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Optimization Now

   

Portfolio Optimization

Compute new portfolio that will generate highest expected return given your specified tolerance for risk
All  Next Launch Module

Use Investing Themes to Complement your Paratek Pharmaceuticals position

In addition to having Paratek Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Manufacturing Thematic Idea Now

Manufacturing
Manufacturing Theme
Companies that provide goods across residential, commercial and industrial construction such as machinery, tools, or lumber production. The Manufacturing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Manufacturing Theme or any other thematic opportunities.
View All  Next Launch
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Other Consideration for investing in Paratek Stock

If you are still planning to invest in Paratek Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Paratek Pharmaceuticals' history and understand the potential risks before investing.
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals